- European Commission approved DZUVEO (sufentanil sublingual tablet, 30 mcg) for the management of acute moderate-to-severe pain in adults in medically monitored settings
- June 30, 2018 cash and short-term investments balance of $50.1 million
- Combined R&D and G&A expenses declined 27% from H1 2017
PR Newswire
REDWOOD CITY, Calif., Aug. 2, 2018